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Physical activity, sleep, and fatigue 
in community dwelling Stroke 
Survivors
Anthony I. Shepherd  1, Richard Pulsford2, Leon Poltawski3, Anne Forster4, Rod S. Taylor3,  
Anne Spencer3, Laura Hollands  3, Martin James3,5, Rhoda Allison6, Meriel Norris7, Raff Calitri  3 
& Sarah G. Dean3
Stroke can lead to physiological and psychological impairments and impact individuals’ physical 
activity (PA), fatigue and sleep patterns. We analysed wrist-worn accelerometry data and the Fatigue 
Assessment Scale from 41 stroke survivors following a physical rehabilitation programme, to examine 
relationships between PA levels, fatigue and sleep. Validated acceleration thresholds were used to 
quantify time spent in each PA intensity/sleep category. Stroke survivors performed less moderate to 
vigorous PA (MVPA) in 10 minute bouts than the National Stroke guidelines recommend. Regression 
analysis revealed associations at baseline between light PA and fatigue (p = 0.02) and MVPA and sleep 
efficiency (p = 0.04). Light PA was positively associated with fatigue at 6 months (p = 0.03), whilst 
sleep efficiency and fatigue were associated at 9 months (p = 0.02). No other effects were shown at 
baseline, 6 or 9 months. The magnitude of these associations were small and are unlikely to be clinically 
meaningful. Larger trials need to examine the efficacy and utility of accelerometry to assess PA and 
sleep in stroke survivors.
In the five years after a stroke, an individuals’ odds of having a residual impairment is one in three1 which equates 
to more than 300,000 people in the UK alone2. Residual effects of stroke are the leading cause of chronic physio-
logical and psychological disability3 and these effects can have deleterious consequences on an individual’s level 
of physical activity (PA)4 and sleep patterns5.
Traditional reporting methods for quantifying PA such as diaries and self-report tools have poor completion 
rates6, limited utility to distinguish between dimensions of PA7, are prone to recall bias, and have insufficient sen-
sitivity to detect small changes in PA around interventions, particularly incidental light intensity PA which is spo-
radic and very difficult to recall accurately. These issues are potentially exacerbated in clinical populations such as 
stroke survivors8, especially if they have aphasia or impaired hand-writing function. Waterproof and continuous 
wear wrist worn (non-affected arm) accelerometers provide a viable option to quantify PA in stroke survivors, as 
to date there is limited evidence of sufficient quality to provide an accurate overview of PA in stroke survivors9,10.
UK national stroke guidelines recommend that stroke survivors participate in 150 minutes per week of mod-
erate to vigorous PA (MVPA) in bouts of at least 10 minutes11. However, relatively few (42%) stroke survivors 
appear to meet the National Stroke guidelines for minutes per week of PA4,12. In addition to physical impairments, 
this may at least in part be explained by an individual’s perception of fatigue which is also known to reduce 
health-related quality of life13. Fatigue in stroke survivors is debilitating and is a common symptom, although its 
aetiology has yet to be elucidated14. If fatigued individuals reduce PA levels symptoms of fatigue often worsen15. 
In contrast, if individuals with fatigue perform exercise their symptoms often improve16 which suggests PA levels 
are interlinked with fatigue. Evidence also suggests fatigue may be related to sleep disorders in stroke survivors13.
Reductions in cognitive function following a stroke3 have been well characterised17,18 and have been linked to 
reductions in functional ability19. This may, at least in part, be due to lower levels of sleep quality in stroke survi-
vors5,20–22. Reduction in sleep quality or prolonged sleep deprivation have been associated with a decline in health 
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related quality of life, psychological wellbeing and physical performance in both healthy individuals and those 
with chronic disease23,24. PA has been shown to improve quality of sleep25. Interventions aimed at increasing PA 
and therefore sleep quality, may provide a novel pathway to improve quality of life and enable stroke survivors to 
regain independence.
Accelerometry is widely used to objectively quantify PA and sedentary periods such as sleep in active indi-
viduals26–28. However, to date there is limited evidence of sufficient quality to provide an accurate overview of PA 
or sleep in stroke survivors9,10. The gold standard assessment of sleep quality is polysomnography, however, this 
technique is both resource intensive and intrusive for the participant. Other methods include sleep diaries and 
self-reported questionnaires but these can lack accuracy29. Accelerometers are also increasingly being used as a 
tool to quantify sleep quality and efficiency30,31 as they are relatively inexpensive and are not burdensome.
In this paper we present exploratory analyses of data collected by accelerometers during the ReTrain trial32 - a 
randomised controlled trial of a physical rehabilitation training programme.
We aimed to determine the utility and acceptability of wrist worn accelerometers in community dwelling 
stroke survivors and to quantify stroke survivors’ levels of PA, sleep quantity and sleep efficiency. We then tested 
two hypotheses: (1) by utilising objectively measured PA (accelerometers), stroke survivor’s will perform lower 
amounts of PA compared to the recommendations and (2) that there will be associations, longitudinally at 6 and 
9 months post intervention between PA, fatigue and sleep.
Methods
Design. A cross-sectional analysis of baseline data and predictive longitudinal analysis of 6 and 9 months 
follow up data from the participants in the ReTrain trial. The trial protocol32 and main results33 of the 12 week 
intervention and 6 and 9 month follow up have been published elsewhere and are summarised here.
Participants. ReTrain aimed to recruit 48 community dwelling stroke survivors. Ethical approval was granted 
by the Cornwall and Plymouth NRES Committee (15/SW/0074) and the study was registered as a clinical trial on 
the ClinicalTrials.gov website, ID No. NCT02429180 (date of registration: 16/04/2015). This study was performed 
in accordance with the relevant guidelines and regulations outlined by the NRES committee. All participants 
provided written informed consent prior to entering the trial.
Inclusion criteria were: confirmation of stroke via their general practitioner, a minimum of 1 month post 
discharge from an NHS rehabilitation programme, ability to walk independently indoors with an aid but with 
(self-reported) difficulties with stairs or uneven surfaces, willingness to be randomised, and capacity to consent. 
Those younger than 18 years of age or with contraindications to moderate to vigorous PA were excluded34.
Data collection. During an initial baseline visit an accelerometer, programmed to record movement data 
for 7 consecutive days, was fitted to the participant’s non-affected arm. Participants were also asked to com-
plete a questionnaire booklet including the Fatigue Assessment Scale, a validated 10 item questionnaire with a 5 
point Likert scale (with scores ranging from 10–50 with 10 representing no fatigue and 50 always fatigued)35,36. 
The minimal clinical meaningful difference (MCMD) is ≥437. A minimum of 7 days later a second assessment 
visit was arranged to collect the accelerometer and questionnaire booklet. These data collection methods were 
repeated 6 and 9 months later.
Assessment of physical activity and sleep. PA and sleep were assessed using wrist-worn accelerometers 
(GENEActiv, Activinsights, Kimbolton, Cambridge, UK). These devices have previously been validated for use in 
healthy adult populations38 and are extensively used in clinical studies. The GENEActiv accelerometers measured 
triaxial movement acceleration in gravity (g) units (1 g = 9.81 m/s2) at a frequency of 100 Hz continuously over a 
period of 7 days. The Euclidean norm (magnitude) of signals from the three axes minus 1 g (with negative num-
bers rounded zero) was used to quantify acceleration due to movement in mg (1 mg = 0.00981 m/s2)39. Following 
the measurement period, data were downloaded using manufacturers software and processed in R (R Core Team, 
Vienna, Austria) using the open source GGIR software package (http://cran.r-project.org).
Previously validated acceleration threshold values (in healthy adults)38 were used to quantify the time (min-
utes/day) spent on average in each intensity category: total PA, and separately for light, moderate, vigorous inten-
sities and the composite category moderate-vigorous PA (MVPA). To facilitate comparison with current national 
stroke guidelines for PA11, average MVPA accumulated in bouts of at least 10 minutes was also calculated.
Sleep was determined from accelerometer data using an open source sleep detection algorithm in GGIR soft-
ware. Sleep metrics derived using this method have demonstrated good levels of agreement with both self-report 
measures of sleep and polysomnography (the gold standard). The method of accelerometer based sleep quantifi-
cation used here is described in detail elsewhere40. Briefly, wrist-worn triaxial accelerometers allow approxima-
tion of the angle of orientation of the arm relative to the horizontal plane. Periods of sleep are defined as nocturnal 
periods characterised by minimal movement frequency and magnitude of changes to the angle of the arm which 
does not include day time sleep. Time in bed was defined as the onset of the first period of sustained inactivity (as 
measured by changes of less than 5 degrees in a rolling 5 minute window) to the end of the last period of inactiv-
ity. Sleep duration is the sum of all recorded periods of sleep. Sleep efficiency can then be calculated as the sleep 
duration as a proportion of time in bed.
Periods of accelerometer non-wearing were identified using the range and standard deviation (SD) of accel-
eration values at each axis, calculated for rolling 60 minute windows. Non-wearing was indicated if the SD 
was <13.0 mg or if the range of values was <50 mg for two of the three axes. A full explanation of this method 
can be found elsewhere39. To allow effective assessment of habitual PA and sleep, measurement days when the 
accelerometer had been worn for less than 16 hours were excluded from the final analyses39,41. Participants who 
recorded less than 4 days of 16 hours were also excluded. A significant number of participants had hemiparesis, 
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therefore the research team offered all participants in the trial assistance with fitting the accelerometers to their 
non-affected wrist (at baseline, 6 m and 9 m follow up).
Statistical analysis. Data are presented as means and standard deviation (SD). Change scores from base-
line to 6 months post randomisation and baseline to 9 months post randomisation were calculated for total 
PA, light PA, moderate PA, MVPA, and vigorous PA categories, time in bed, sleep time, sleep efficiency and 
self-reported fatigue. A series of multivariate linear regression models were fitted to estimate (1) the contribution 
of PA and sleep efficiency to fatigue (at baseline and change in these variables over 6 months and 9 months), and 
(2) the contribution of PA and fatigue to sleep efficiency (at baseline and change in these variables over 6 months 
and 9 months). All models were adjusted for gender, age, time since stroke, simplified modified Rankin scale (a 
scale to measure an individual’s degree of disability). Models assessing change in fatigue or sleep efficiency were 
also adjusted for baseline fatigue and sleep efficiency. Statistical significant differences were accepted at p < 0.05. 
Statistical analyses were performed on SPSS software version 22.0 (Chicago, IL). All data generated or analysed in 
this study are included in this published article (and its supplementary information files).
Results
Fifty stroke survivors consented to participate in the ReTrain trial (see Table 1 for participant characteristics). 
Forty-one participant data sets were eligible for analysis as four participants were excluded and one participant 
withdrew prior to randomisation. Three participants were excluded from the accelerometer analysis (for inade-
quate wear time) and one was lost to follow up (accelerometer not tolerated). For detailed analysis of participant 
flow through the study and reasons for withdrawal from the trial see Fig. 1.
Compliance with the wrist worn accelerometers was very high. Participants averaged 4.0 ± 0.3 valid days of 
wear time for weekdays and 2.0 ± 0.2 days for weekend wear. Of the 45 participants that entered the baseline 
assessment period, 42 participants (93%) achieved or surpassed the wear time criteria of 16 hours / day, 4 days a 
week at each measurement stage.
Description and quantification of PA in community dwelling stroke survivors. Our sam-
ple completed on average 155 minutes of total PA per day. Average minutes of total PA were split into light PA 
(101 ± 104 minutes), moderate PA (52 ± 54 minutes), vigorous PA (2 ± 4 minutes) and the combined variable 
MVPA (54 ± 56 minutes). On average (across measurement days) only 7 (±17) minutes per day of MVPA was 
accumulated in bouts of MVPA of over 10 minutes, see Fig. 2. Only 15% (n = 5) of our cohort achieved a 10 min 
bout of MVPA at baseline, which increased to 17% (n = 7) and 19% (n = 8) respectively at 6 and 9 months.
Sleep quantity and efficiency. This cohort spent on average 10 hours in bed and 7.4 hours of that time 
asleep, equating to 74% sleep efficiency. Data from accelerometers are presented for sleep indices and self-reported 
fatigue in Table 2.
Characteristics Sub categories
Mean ± SD and/or 
percentage
Male n (%) 27 (66)
Age (years): 70 ± 11
Time since stroke (months) 60 ± 47
Type of stroke n (%)
Haemorrhagic 4 (10)
Ischaemic 29 (71)
Both 1 (2)
Missing 7 (17)
Co-morbidities, n (%)
Hypertension 32 (78)
Type 2 Diabetes Mellitus 7 (17)
Depression 11 (27)
Chronic Kidney Disease 2 (5)
Asthma / COPD 6 (15)
Other 7 (17)
MMSE 28 (68)
Functional Disability (MRS) n (%)
0 1 (2)
1 3 (7)
2 13 (32)
3 24 (59)
Table 1. Characteristics of participants (n = 41) included in the final analysis. MRS, Modified Rankin Scale. 
Some participants had multiple co-morbidities. Abbreviations, mini mental state examination (MMSE) and 
chronic obstructive pulmonary disease (COPD).
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Exploratory analysis of associations between PA, sleep and fatigue. At baseline there was little 
evidence that PA was associated with fatigue (Table 3, model 1) or sleep efficiency (Table 4, model 1). Although 
there were statistically significant associations between light PA and fatigue (for every 10 minutes of light PA 
fatigue levels were 0.3 points lower) and MVPA and sleep efficiency (for every 10 minutes of MVPA sleep effi-
ciency was 0.01 percentage points higher), these were very both small associations and unlikely to reflect any 
clinically meaningful change (MCMD ≤4 point change). There were also small levels of association between sleep 
efficiency and fatigue.
There was also little evidence that changes in PA levels were linked to changes in fatigue (Table 3, models 2 
and 3) or sleep efficiency (Table 4, model 2 s and 3) at 6 or 9 months. However, we did find a statistically signifi-
cant change in fatigue at 6 months suggesting that light PA was positively associated with fatigue: an increase of 
10 minutes of light PA was associated with an increase in fatigue of 0.3 points (range of measure; 10–50). Sleep 
efficiency and fatigue were associated at 9 months but not at 6 months. At 9 months for every 1 percentage point 
increase in sleep efficiency there was a 44 point decrease (range of measure; 10–50) in fatigue (Table 3). A 1 point 
increase in fatigue was associated with a 0.01 percentage point decrease in sleep efficiency (Table 4). In addition, 
the effect of trial arm (control or intervention) was not significant, as expected, as the study was a pilot and was 
not set up to show statistically significant changes.
Discussion
We have provided a robust quantification of PA and sleep in community dwelling stroke survivors. The cohort 
exhibited excellent compliance in wearing the devices and has provided the most robust and detailed objective 
analysis of stroke survivors PA and sleep efficiency to date. We found that stroke survivors performed significantly 
less MVPA in bouts of 10 minutes than recommended by the National Stroke guidelines at baseline and during 
follow up. We found small but statistically significant associations between PA, fatigue, and sleep efficiency.
While the cohort accumulated on average over 45 minutes per day of MVPA at each measurement point, the 
vast majority of this activity consisted of very short sporadic bouts of movement consistent with normal life-
style activities10,42 rather than the more sustained (>10 minutes) bouts of volitional activity recommended for 
improvements in health for this patient group11. Less than one fifth (15–19% respectively) of our cohort perfumed 
a 10 minutes bout of MVPA at each data collection time point. In addition the cohort accumulated on average only 
2 minutes of vigorous intensity PA per day across the week. Overall our data suggests that this cohort of stroke 
survivors accumulate the majority of their physical activity at the lower intensities, which may be insufficient to 
influence physical recovery or reduce risk of a subsequent stroke. Despite increasing evidence for the feasibility and 
acceptability of the use of wrist worn accelerometers in clinical studies33, evidence for accelerometer use to quantify 
PA in stroke survivors is sparse. Larger studies that utilise robust methodologies similar to this study (adequate 
wear time with patient friendly wrist-worn devices) are required to characterise PA in stroke survivors.
Figure 1. Flow diagram of the study.
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Changes in PA are linked with changes in fatigue profiles in individuals with chronic fatigue15,16, and in stroke 
survivors43. We showed that higher levels of light intensity PA were associated with reduced levels of fatigue at 
baseline and 9 months, but not at 6 months. We showed that for every 10 minutes of light PA fatigue levels were 
0.3 points lower. Although these changes were statistically significant, we do not have sufficient statistical power 
in this study to confidently determine if they represent clinically meaningful changes. However, at 6 months, 
time spent in MVPA is reduced and light PA is increased. One suggestion is that the increase in light PA maybe 
displacing sleep or sedentary time. Regardless of the aforementioned limitations, the potential for light PA to be 
associated with reduced fatigue would suggest that further research into PA in stroke survivors is warranted. A 
larger definitive trial of ReTrain may be able to elucidate the effects of a training programme designed to improve 
functional ability, including investigating the impact on fatigue profiles in stroke survivors.
Stroke survivors have reduced sleep quality5,20–22 which can have profound effects on quality of life23,24. In line 
with evidence in healthy individuals25, we show the more time spent in PA or MVPA the more efficient a stroke 
survivor’s sleep is likely to be. However, this change is very small (with 10 minutes of MVPA sleep efficiency is 
higher by only 0.01 percentage points) and may not affect an individual’s quality of life. There was no association 
between light intensity PA and sleep efficiency which suggests that higher intensities of PA may be needed to 
obtain better quality (more efficient) sleep. Fatigue has previously been reported to be related to sleep disorders 
in stroke survivors13 and we show similar associations. However, the very wide confidence intervals around the 
measurement of fatigue (at both baseline and over time) should also be noted as they highlight an imprecise esti-
mate of change, as would be expected from the small sample size.
Figure 2. Average PA at baseline, 6 months and 9 months follow up. Mean ± SD in minutes for light PA (A), 
moderate PA (B), MVPA (C), Vigorous PA (D), Total PA (E) and MVPA in 10 minute bouts (F). For MVPA 
(F), the dashed line represents the minimum bout length and the dotted line represents the minimum level of 
MVPA in minutes per day for stroke survivors according to the National Stroke guidelines.
Measures Mean
Quartiles Change at 6 months 
(n = 37)
Change at 9 months 
(n = 32)25 50 75
Sleep (hours) 7.4 ± 1.2 6.4 7.2 8.2 −0.0 ± 0.8 −0.2 ± 1.3
Time in bed (hours) 10 ± 1.2 9.2 10.1 11 −0.0 ± 0.8 −0.0 ± 1.0
Sleep Efficiency (%) 74 ± 10 66 75 80 0.0 ± 0.1 0.0 ± 0.1
Fatigue 26 ± 7 20 25 30 −2.7 ± 4.0 1.6 ± 5.1
Table 2. Accelerometry based description of sleep in community dwelling stroke survivors. Fatigue, assessed 
via the fatigue assessment scale. Data are the mean ± SD or as quartiles.
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Accelerometers were utilised to quantify both PA and sleep in this study. We demonstrated excellent compli-
ance with the wrist worn accelerometers with 93% of participants surpassing the inclusion criteria for accelerom-
eter wear time of 16 hours per day, 4 days a week. Earlier in the manuscript we highlight that other methods of 
quantifying sleep (polysomnography) can be resource intensive and intrusive to the participant. Due to a signif-
icant number of people having hemiparesis, the research team offered all participants in the trial assistance with 
fitting the accelerometers (in the participant’s home). All participants took up the offer and were visited on three 
occasions (at baseline, 6 m and 9 m follow up). This has significant resource use implications, however, this was 
mitigated as visits were scheduled alongside pre-planned assessment visits required by the pilot trial.
There are some limitations to our study. First, the ReTrain trial was not statistically powered to perform infer-
ential analyses on study outcomes and the exploratory results from the regression models should be interpreted 
with caution. These analyses and processes have been utilised as a rehearsal for the definitive trial of ReTrain. 
Secondly, to date there are currently no established accelerometer cut-points to delineate activity intensity in 
stroke survivors. The cut-points used in the present study were developed using a non-clinical population which 
Measures
(1) Baselinea (2) 6 Monthsb (3) 9 Monthsb
Coefficient 95% CIs p-value Coefficient 95% CIs p-value Coefficient 95% CIs p-value
Constant 55.37 29.88; 80.88 0.001 −1.89 −22.62; 18.84 0.85 −25.59 −55.45; 3.28 0.08
Trial Arm −0.14 −4.67; 4.40 0.95 −2.16 −4.88; 0.56 0.11 1.74 −2.05; 5.54 0.35
Gender −7.57 −12.75; −2.38 0.006 4.94 1.45; 8.42 0.01 4.03 −0.68; 8.73 0.09
Age −0.08 −0.34; 0.18 0.56 −0.07 −0.23; 0.10 0.42 0.22 −0.04; 0.47 0.09
Time since stroke −0.01 −0.06; 0.05 0.84 0.01 −0.03; 0.04 0.69 −0.03 −0.07; 0.02 0.24
sMRS 0.07 −4.63; 4.77 0.98 3.36 0.42; 6.57 0.04 0.71 −4.22; 5.63 0.77
Baseline Light PA −0.03 −0.06; −0.01 0.02 0.01 −0.01; 0.03 0.29 0.01 −0.01; 0.03 0.32
Baseline MVPA 0.02 −0.03; 0.07 0.46 −0.03 −0.07; 0.01 0.17 0.01 −0.04; 0.06 0.66
Baseline Sleep efficiency −25.14 −50.46; 0.19 0.05 0.39 −18.21; 18.99 0.97 8.18 −18.75; 35.10 0.53
Baseline Fatigue — — — 0.05 −0.18; 0.28 0.65 0.16 −0.18; 0.50 0.34
Change in Sleep Efficiency — — — 0.82 −20.18; 21.81 0.94 −44.01 −80319; −7.83 0.02
Change in Light PA — — — 0.03 0.00; 0.05 0.03 0.01 −0.02; 0.04 0.55
Change in MVPA — — — 0.02 −0.04; 0.08 0.45 −0.01 −0.11; 0.08 0.79
R2 0.35 0.47 0.54
Table 3. Self-reported fatigue based on average total Light PA, average total MVPA and sleep efficiency: 
models examining (1) fatigue at baseline, (2) fatigue change at 6 months; (3) fatigue change at 9 months. aModel 
adjusted for trial arm, gender, age, time since stroke, simplified modified rankin scale (sMRS), baseline sleep 
efficiency. bModel adjusted for gender, age, time since stroke, simplified modified rankin scale (sMRS), baseline 
sleep efficiency, baseline fatigue.
Measures
(1) Baselinea (2) 6 Monthsb (3) 9 Monthsb
Coefficient 95% CIs p-value Coefficient 95% CIs p-value Coefficient 95% CIs p-value
Constant 0.77 0.44; 1.10 0.00 −0.01 −0.42; 0.42 0.98 −0.14 −0.49; 0.21 0.41
Trial Arm −0.03 −0.09; 0.03 0.31 −0.00 −0.06; 0.06 0.98 0.01 −0.03; 0.06 0.54
Gender −0.02 −0.10; 0.06 0.62 0.02 −0.06; 0.10 0.64 0.03 −0.02; 0.09 0.22
Age 0.00 0.00; 0.01 0.50 0.00 −0.00; 0.01 0.10 0.00 −0.00; 0.01 0.18
Time since stroke 0.00 0.00; 0.00 0.85 0.00 −0.00; 0.00 0.29 0.00 −0.00; 0.00 0.15
MRS 0.03 −0.03; 0.09 0.33 −0.06 −0.13; 0.01 0.07 −0.03 −0.08; 0.03 0.27
Baseline Light PA 0.00 0.00; 0.00 0.32 0.00 0.00; 0.00 0.17 0.00 0.00; 0.00 0.17
Baseline MVPA 0.001 0.00; 0.00 0.04 0.00 −0.00; 0.00 0.51 0.00 0.00; 0.00 0.42
Baseline Fatigue −0.01 −0.01; 0.00 0.05 0.00 −0.00; 0.01 0.78 0.00 0.00; 0.01 0.19
Baseline Sleep efficiency — — — −0.24 −0.60; 0.12 0.18 −0.10 −0.38; 0.24 0.63
Change in Fatigue — — — 0.00 −0.01; 0.01 0.94 −0.01 −0.01; −0.00 0.02
Change in Light PA — — — 0.00 −0.00; 0.00 0.46 0.00 0.00; 0.00 0.76
Change in MVPA — — — −0.00 −0.00; 0.00 0.07 0.00 0.00; 0.00 0.88
R2 0.29 0.43 0.56
Table 4. Sleep efficiency based on average total Light PA, average total MVPA and fatigue: models examining 
(1) sleep efficiency at baseline, (2) sleep efficiency change at 6 months; (3) sleep efficiency change at 9 months. 
aModel adjusted for trial arm, gender, age, time since stroke, simplified modified rankin scale (MRS), baseline 
sleep efficiency. bModel adjusted for gender, age, time since stroke, simplified modified rankin scale (MRS), 
baseline sleep efficiency, baseline fatigue.
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likely had a slightly higher level of cardiorespiratory fitness. This could increase the likelihood of misclassification 
of PA intensity. However in the present study this misclassification would have been consistent across time points 
and as such likely had little influence on estimates of change in PA from baseline. Future research is needed to 
establish PA intensity cut-points to better classify PA in stroke survivors. Larger powered studies aimed at estab-
lishing the clinically meaningful change in PA that is required to improve sleep efficiency are also required. A final 
limitation is that all participants had some degree of mobility impairment, whilst not all stroke survivors have an 
impairment this may at least in part explain the low levels of PA.
Using reliable, objective measures and with existing cut-points for non-clinical populations we showed that 
stroke survivors were performing less MVPA than recommended when compared against National Stroke guide-
lines, with less than one fifth performing these in more than 10 minute bouts. We found small but statistically 
significant levels of association between PA, fatigue and sleep efficiency. Light PA warrants further examination 
in stroke survivor’s as we show significant associations with fatigue and that the majority of stroke survivors do 
not meet the MVPA bout length recommendations. Larger studies are needed to examine the efficacy of utilising 
accelerometers to assess sleep in stroke survivors.
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